Alterola Financial Statements From 2010 to 2024
| ABTI Stock | USD 0.01 0 32.76% |
Check Alterola Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alterola Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Alterola financial statements analysis is a perfect complement when working with Alterola Biotech Valuation or Volatility modules.
Alterola |
Alterola Biotech Company Price To Book Analysis
Alterola Biotech's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Alterola Biotech Price To Book | 6.29 X |
Most of Alterola Biotech's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alterola Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Alterola Biotech has a Price To Book of 6.2902 times. This is 75.51% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to book for all United States stocks is 33.86% higher than that of the company.
Alterola Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alterola Biotech's current stock value. Our valuation model uses many indicators to compare Alterola Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alterola Biotech competition to find correlations between indicators driving Alterola Biotech's intrinsic value. More Info.Alterola Biotech is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Alterola Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Alterola Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Alterola Biotech Financial Statements
Investors use fundamental indicators, such as Alterola Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Alterola Biotech's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products production of active pharmaceutical ingredients and food-grade ingredients and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Alterola Pink Sheet
Alterola Biotech financial ratios help investors to determine whether Alterola Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterola with respect to the benefits of owning Alterola Biotech security.